Peripheral monocytes and CD4+ cells are potential sources for increased circulating levels of TGF-β and substance P in autoimmune myelofibrosis

American Journal of Hematology

Volumn 81, Issue 1, 2006, Pages 51-58

  Harrison, Jonathan S ^a   Corcoran, Kelly E ^a   Joshi, Deval ^a   Sophacleus, Constantin ^a   Rameshwar, Pranela ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Autoimmune myelofibrosis; CD4+; Peripheral monocytes; Substance P; TGF

Indexed keywords

SUBSTANCE P; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE MYELOFIBROSIS; CASE REPORT; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; INFLAMMATION; MALE; MONOCYTE; MYELOFIBROSIS; NEOPLASM; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; BLOOD CELL COUNT; CD4-POSITIVE T-LYMPHOCYTES; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MONOCYTES; MYELOFIBROSIS; PANCYTOPENIA; SUBSTANCE P; TRANSFORMING GROWTH FACTOR BETA;

EID: 30444441635     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20439     Document Type: Article

References (18)

1. McCarthy DM. Fibrosis of the bone marrow: content and causes. Br J Haematol 1985;59:1-7.
2. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 1999;17:2954-2970.
3. Tifferi A. Medical progress: myelofibrosis with myeloid metaplasia. N Engl J Med 2000;342:1255-1265.
4. Viallard JF, Parrens M, Boiron JM, Texier J, Mercie P, Pellegrin JL. Reversible myelofibrosis induced by tuberculosis. Clin Infect Dis 2002;34:1641-1643.
5. Aharon A, Levy Y, Bar-Dayan Y, et al. Successful treatment of early secondary myelofibrosis in SLE with IVIG. Lupus 1997;6:408-411.
6. Rameshwar P, Narayanan R, Qian J, Denny T, Colon C, Gascon P. NF-kappa B as a central mediator in the induction of TGF-β in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis. J Immunology 2000;165:2271-2277 (PMID 10925316).
7. Rameshwar P, Oh HS, Yook C, Gascon P, Chang V. Substance P-fibronectin-cytokine interactions in myeloproliferative disorders with bone marrow fibrosis. Acta Haematol 2003;109:1-10.
8. Bass RD, Pullarkat V, Feinstein DI, Kaul A, Winberg CD, Brynes RK. Pathology of autoimmune myelofibrosis. A report of three cases and a review of the literature. Am J Clin Pathol 2001;116: 211-216.
9. Lawrence DA. Identification and activation of latent transforming growth factor β. Methods Enzymol 1991;198:327-336.
10. Rameshwar P, Chang VT, Thacker UF, Gascon P. Systemic transforming growth factor β in patients with bone marrow fibrosis-pathophysiologic implications. Am J Hematol 1998;59: 133-142.
11. Rameshwar P, Poddar A, Zhu G, Gascon P. Receptor induction regulates the synergistic effects of substance P with IL-1 and PDGF on the proliferation of bone marrow fibroblasts. J Immunol 1997;158:3417-3424.
12. Rameshwar P, Chang VT, Gascón P. Implication of CD44 in adhesion-mediated overproduction of TGF-β and IL-1 in monocytes from patients with bone marrow fibrosis. Br J Haematol 1996;93:22-29.
13. Bergeron A, Soler P, Kambouchner M, et al. Cytokine profiles idiopathic pulmonary fibrosis suggest an important role for TGF-beta and IL-10. Eur Respir J 2003;22:69-76.
14. Rameshwar P, Narayanan R, Qian J, Denny TN, Colon C, Gascon P. NF-κB as a central mediator in the induction of TGF-β in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis. J Immunol 2000;165:2271-2277.
15. Pullarkat V, Bass RD, Gong JZ, Feinstein DI, Byrnes RK. Primary autoimmune myelofibrosis: definition of a distinct clinicopathologic syndrome. Am J Hematol 2003;72:8-12.
16. Blobe G, Schiemann W, Lodish H. Role of transforming growth factor β in human disease. New Engl J Med 2000;342: 1350-1358.
17. Kloen P, Jennings CL, Gebhardt MC, Springfield DS, Mankin HJ. Suramin inhibits growth and transforming growth factor-beta 1 (TGF-beta 1) binding in osteosarcoma cell lines. Eur J Cancer 1994;30A:678-682.
18. Patel L, Lindley C. Aprepitant - a novel NKI-receptor antagonist. Expert Opin Pharmacother 2003;4:2279-2296.